Ninerafaxstat

Ninerafaxstat (IMB-1018972) is a novel orally active cardiac mitochondrial drug that restores myocardial energy homeostasis. Ninerafaxstat competitively inhibits 3-ketoacyl-CoA thiolase (3-KAT) to partially suppress fatty acid oxidation, and shifts cardiac energy metabolism from free fatty acid oxidation to glucose oxidation, regulating myocardial substrate utilization and thereby improving cardiac efficiency. Ninerafaxstat can be used for research on cardiovascular diseases[1][2].

Product Specifications

CAS Number

[2254741-41-6]

Product Name Alternative

IMB-1018972; IMB-101

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Mitochondrial Metabolism

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Metabolic Disease; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/ninerafaxstat.html

Purity

99.14

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(C1=CC=CN=C1)OCCN2CCN(CC2)CC3=CC=C(C(OC)=C3OC)OC

Molecular Formula

C22H29N3O5

Molecular Weight

415.48

Precautions

H302, H315, H319, H335

References & Citations

[1]Moritz Hundertmark MD, et al. Kiosk 11R-TC-08 - Ninerafaxstat Modulates Cardiac Energy Metabolism in Cardio-metabolic Syndromes: A Mechanistic, Hyperpolarized MR Trial. Journal of Cardiovascular Magnetic Resonance. 2024; 26: 100325.|[2]Paul Chamberlin, et al. IMB-1018792, A NOVEL FIRST-IN CLASS PARTIAL FATTY ACID OXIDATION INHIBITOR IMPROVES CARDIAC REMODELING AND FUNCTION POST-MYOCARDIAL INFARCTION. J Am Coll Cardiol. 2021 May 11;77 (18) :539.